Live Analyst Rating Changes 53182 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kallum Titchmarsh
MS

Kallum Titchmarsh

Morgan Stanley
Wall Street Analyst
★★★★★
#61
on 13Foresight · ranked by our own returns
73%
Success Rate
+9.5%
Average Return
86 of 118 calls profitable · +7.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 73% of Kallum Titchmarsh's ratings turned a profit when each position was held for 1 year — averaging +9.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

61 Buy 83 Hold 6 Sell
Kallum's Stock Coverage 30 ratings · 2026-11-03
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GH
Guardant Health
 Oct 20, 2026 BUY Strong Buy
-3.1% avg upside
33 analysts
$200.00
11.77% Upside
 +7.6% ·
GRAL
GRAIL Inc
 Oct 13, 2026 HOLD Strong Buy
-18.5% avg upside
9 analysts
$120.00
16.29% Downside
 -0.7% ·
TXG
10x Genomics
 Oct 13, 2026 HOLD Buy
-7.5% avg upside
19 analysts
$70.00
0.08% Downside
 -2.3% ·
ADPT
Adaptive Biotechnologies
 Oct 13, 2026 HOLD Strong Buy
+1.9% avg upside
17 analysts
$27.00
1.44% Upside
 +3.0% ·
AVTR
Avantor
 Oct 13, 2026 HOLD Buy
+4.5% avg upside
27 analysts
$15.00
6.53% Downside
 +0.3% ·
NTRA
Natera
 Oct 13, 2026 BUY Strong Buy
-13.2% avg upside
28 analysts
$435.00
5.01% Upside
 -1.8% ·
TMO
Thermo Fisher
 Oct 13, 2026 BUY Strong Buy
-5.2% avg upside
40 analysts
$730.00
4.75% Upside
 +5.1% ·
DHR
Danaher
 Oct 13, 2026 BUY Strong Buy
-4.4% avg upside
47 analysts
$240.00
3.31% Upside
 +3.3% ·
A
Agilent
 Oct 13, 2026 BUY Strong Buy
-8.1% avg upside
35 analysts
$190.00
8.59% Upside
 +2.2% ·
CRL
Charles River Labs
 Oct 13, 2026 BUY Strong Buy
-28.4% avg upside
36 analysts
$340.00
5.38% Downside
 +18.3% ·
CTKB
Cytek Biosciences
 Oct 09, 2026 HOLD Buy
-4.1% avg upside
5 analysts
$5.00
18.43% Downside
 +12.9% ·
MTD
Mettler-Toledo
 Oct 09, 2026 HOLD Buy
-26.0% avg upside
19 analysts
$1575.00
5.95% Downside
 +8.1% ·
STVN
Stevanato Group
 Oct 05, 2026 HOLD Strong Buy
+38.0% avg upside
14 analysts
$20.00
3.13% Upside
 -1.6% ·
WST
West Pharmaceutical Services
 Sep 22, 2026 BUY Strong Buy
-6.0% avg upside
18 analysts
$400.00
2.99% Downside
 +9.7% ·
MMED
MiniMed Group, Inc.
 Sep 18, 2026 BUY Strong Buy
+37.6% avg upside
17 analysts
$21.00
14.82% Upside
 -16.1% ·
IQV
IQVIA Holdings
 Sep 17, 2026 HOLD Strong Buy
-2.5% avg upside
40 analysts
$270.00
0.92% Upside
 -2.3% ·
WAT
Waters
 Sep 14, 2026 HOLD Strong Buy
-12.6% avg upside
31 analysts
$430.00
7.11% Downside
 +12.9% ·
HTFL
HeartFlow, Inc.
 Aug 17, 2026 HOLD Strong Buy
-24.3% avg upside
10 analysts
$40.00
32.30% Downside
 +40.8% ·
VCYT
Veracyte
 Aug 04, 2026 SELL Strong Buy
+4.5% avg upside
19 analysts
$44.00
12.08% Downside
 -8.4% ·
TEM
Tempus AI, Inc. Class A
 Jul 10, 2026 BUY Buy
-0.3% avg upside
25 analysts
$70.00
3.12% Downside
 +33.6% ·
PSNL
Personalis
 Jul 09, 2026 HOLD Buy
-6.0% avg upside
11 analysts
$13.00
17.87% Downside
 +7.5% ·
GMED
Globus Medical
 Jul 15, 2025 BUY Strong Buy
+18.8% avg upside
24 analysts
$68.00
12.78% Downside
 +40.6% ·
INSP
Inspire Medical Systems
 Jul 15, 2025 BUY Buy
+30.4% avg upside
21 analysts
$182.00
167.22% Upside
 -60.6% ·
IRTC
Irhythm Technologies
 Jun 11, 2025 BUY Strong Buy
+32.2% avg upside
21 analysts
$160.00
29.62% Upside
 -23.5% ·
EMBC
Embecta Corporation
 May 20, 2025 HOLD Sell
+60.0% avg upside
5 analysts
$15.00
139.98% Upside
 -73.8% ·
TMCI
Treace Medical Concepts
 May 09, 2025 HOLD Hold
+34.6% avg upside
8 analysts
$10.00
125.75% Upside
 -70.5% ·
SIBN
SI-Bone
 May 06, 2025 BUY Strong Buy
+22.8% avg upside
18 analysts
$19.00
10.47% Downside
 -21.0% ·
PEN
Penumbra
 Apr 24, 2025 HOLD Buy
+3.6% avg upside
23 analysts
$260.00
18.41% Downside
 +10.6% ·
ATEC
Alphatec Holdings
 Feb 27, 2025 HOLD Strong Buy
+116.9% avg upside
23 analysts
$11.00
56.26% Upside
 +12.4% ·
SGHT
Sight Sciences
 Dec 03, 2024 HOLD Buy
+9.7% avg upside
14 analysts
$4.00
57.15% Downside
 +121.8% ·
🔒 25 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kallum Titchmarsh — Frequently Asked Questions
How accurate are Kallum Titchmarsh's stock ratings?
Based on the calls 13Foresight could measure, about 74% of Kallum's ratings were profitable over a one-year hold, with an average return of +9.6% per rating, or +7.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Kallum ranked on 13Foresight?
Kallum Titchmarsh is currently ranked #61 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kallum cover?
Kallum most recently has ratings on GH, GRAL, TXG, ADPT, AVTR, NTRA, TMO, DHR, A, CRL, CTKB, MTD and 18 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.